Blue Cloud Softech approves CareTech AI share swap plan

What the board approved on August 24, 2026

Blue Cloud Softech Solutions Ltd said its Board of Directors has granted in-principle approval to acquire up to 100% of CareTech AI Inc, a healthcare-focused entity based in the United States. The decision was taken at the company’s board meeting held on Monday, August 24, 2026. The proposed transaction is structured as a share swap. The consideration is planned through preferential allotment of equity shares.

The company’s disclosure also makes clear what this approval does not mean. It is not a final agreement, and it does not create a binding commitment at this stage. Key items such as valuation and final commercial terms are still to be determined. The company indicated these will be settled after due diligence and related processes.

Deal structure: preferential allotment and share swap

The proposed acquisition is expected to be executed through a non-cash share swap mechanism. Blue Cloud has indicated the swap would be implemented by issuing equity shares on a preferential basis. This is consistent with what the company had earlier communicated about considering fundraising via preferential issuance of equity shares or other eligible securities, including a share swap as consideration for an acquisition.

The company has not disclosed any monetary value or transaction amount for the CareTech AI acquisition. It also has not disclosed the number of shares that may be issued under the proposed swap. The structure and terms remain subject to valuation, negotiations, and other approvals.

No binding agreement yet, terms subject to due diligence

Blue Cloud said no letter of intent or binding agreement has been executed for the CareTech AI transaction. The company also stated that no binding commitment arises from the in-principle approval. This positions the current update as an initial step rather than a completed acquisition.

The company has stated the proposed transaction is subject to due diligence, valuation, negotiations, applicable statutory and regulatory approvals, and the execution of definitive agreements. The board will evaluate the acquisition based on the outcome of due diligence and valuation work before finalising the transaction terms.

Earlier communication: board meeting notice and trading window closure

Ahead of the August 24 meeting, Blue Cloud had informed stock exchanges that its board would meet to consider a proposal to acquire equity share capital of a US-based healthcare company. The company said the board meeting was scheduled for 4:30 PM at its registered office in Hyderabad.

Following that announcement, the company closed its trading window for designated persons and their immediate relatives with effect from August 17, 2026. The trading window is set to remain closed until 48 hours after the outcome of the board meeting is disclosed to the stock exchanges. The company’s disclosures also indicated the board would consider in-principle approval of the proposed transaction structure, consideration, and commercial terms.

Key facts disclosed so far

Background: Blue Cloud’s recent share-swap precedent with ConnectM

The CareTech AI proposal comes after Blue Cloud’s previously disclosed share exchange transaction with ConnectM Technology Solutions, Inc (OTCQX: CNTM). ConnectM stated that the transaction closed on June 17, 2026 and involved a share-for-shares exchange. Under that transaction, ConnectM transferred its 94.11% ownership interest in Global Impx Inc to Blue Cloud. In return, 160 million newly issued Blue Cloud shares were issued to ConnectM, representing an approximately 17.3% post-issue equity stake.

ConnectM also disclosed that the 160 million Blue Cloud shares issued in that transaction received trading approval from BSE in August 2026. ConnectM described this as the final regulatory step and stated it formally commenced a six-month trading lock-up period under BSE listing guidelines. ConnectM’s earlier communication also referenced BSE granting in-principle approval, clearing a key condition for the preferential allotment.

What the ConnectM disclosures said about valuation and equity impacts

ConnectM disclosed expectations around accounting treatment for the Blue Cloud shares received under the India business transaction. It said it expected to record the Blue Cloud shares as an investment of approximately USD 30.4 million and recognize a non-cash gain of about USD 18.4 million attributable to ConnectM stockholders.

On a pro forma basis, ConnectM said stockholders’ equity was expected to rise to approximately USD 18.8 million at the effective date, compared with approximately USD 2.0 million earlier. It also said the equity level would be above the USD 4.0 million to USD 5.0 million minimum referenced for a U.S. national exchange listing, and that the liabilities-to-equity ratio would improve from about 19x to roughly 1.6x. These figures relate to ConnectM’s disclosures and not to the CareTech AI proposal.

Other disclosed business activity: SpaceX service agreement work

Separately, the provided details also indicate Blue Cloud has begun work on a USD 150 million service agreement with SpaceX International Ltd. No further specifics were included on the scope, timelines, or financial recognition of that service agreement in the supplied text.

Market impact: what investors can and cannot infer

From a market perspective, the immediate trigger is the board’s in-principle approval to pursue the CareTech AI acquisition via a share swap, paired with the explicit confirmation that valuation and final terms are pending. Investors typically track such developments for potential changes to business mix, balance sheet structure, and equity dilution, but Blue Cloud has not provided transaction size, valuation, or share issuance numbers for this proposal.

The disclosures also highlight that regulatory steps matter for share-swap transactions, as shown by the ConnectM transaction where BSE approvals and a lock-up period were explicitly referenced. For the CareTech AI proposal, the company has stated that due diligence and regulatory approvals are still required, and definitive agreements are yet to be executed.

Timeline of the disclosed events

Conclusion

Blue Cloud Softech’s August 24, 2026 update sets out an in-principle plan to acquire up to 100% of US-based CareTech AI Inc through a preferential allotment-based share swap. The company has also been explicit that no binding agreement has been signed and that valuation and final terms remain subject to due diligence, negotiations, and regulatory approvals. The next concrete milestone will be the disclosure of further details, if any, after completion of due diligence and the execution of definitive agreements.